Why the study?
Routine clinical practice-based data on antithrombotic therapy in non-valvular AF are needed to evaluate real-world comparative safety and effectiveness between dabigatran and vitamin K antagonists.
Does dabigatran improve safety and effectiveness outcomes compared to vitamin K antagonists in patients with newly diagnosed non-valvular atrial fibrillation?
Does dabigatran improve safety and effectiveness outcomes compared to vitamin K antagonists in patients with newly diagnosed non-valvular atrial fibrillation?
In real-world clinical practice, dabigatran is associated with significantly lower risks of major bleeding and all-cause mortality compared to vitamin K antagonists in patients with newly diagnosed atrial fibrillation, with comparable stroke prevention.
No takes yet. Share an insight, caveat, or question.
Should not yet change practice; confirms RE-LY benefit-risk in global newly diagnosed AF but leaves residual confounding open.
Huisman et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: